BELITE BIO INC ADR
NASDAQ: BLTE (Belite Bio, Inc)
Last update: 7 hours ago170.96
0.61 (0.36%)
| Previous Close | 170.35 |
| Volume | 90,694 |
| Price / Earnings (Forward) | 434.78 |
| Price / Book | 8.87 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.36 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 25.98 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -33.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Belite Bio, Inc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.93% |
| % Held by Institutions | 0.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,077,219 |
| Maverick Capital Ltd | 30 Jun 2026 | 396,311 |
| Eventide Asset Management, Llc | 30 Jun 2026 | 390,829 |
| Holocene Advisors, Lp | 30 Jun 2026 | 251,035 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 165,000 |
| Mpm Bioimpact Llc | 30 Jun 2026 | 137,208 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHUANG HAO-YUAN | - | 192.85 | -17,962 | -3,463,972 |
| LIN YU-HSIN | - | 192.85 | -26,000 | -5,014,100 |
| Aggregate Net Quantity | -43,962 | |||
| Aggregate Net Value ($) | -8,478,072 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 192.85 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHUANG HAO-YUAN | Officer | 08 Sep 2026 | Automatic sell (-) | 17,962 | 192.85 | 3,463,972 |
| LIN YU-HSIN | Officer | 08 Sep 2026 | Automatic sell (-) | 26,000 | 192.85 | 5,014,100 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |